Rocket Lab: Wall Street’s Optimism Clashes With Insider Profit-Taking

The space economy may be expanding at breakneck speed, but Rocket Lab’s stock is sending mixed signals. While one top analyst has just lifted his price target to $132, the company’s own insiders have been selling shares hand over fist—unloading roughly $67 million worth of stock over the last 90 days. The tension between bullish growth forecasts and cautious insider behavior is creating a duality that investors must weigh ahead of the company’s next earnings report, due either August 5 or August 6 depending on the source.

Stifel Nicolaus analyst Erik Rasmussen reaffirmed his buy rating on Rocket Lab and raised his price target from $110 to $132. The upgrade hinges on the rapid scaling of the company’s business, with particular attention on the upcoming Neutron rocket. That larger launch vehicle is on track for its maiden flight in 2026, and Rocket Lab expects the development to open up a far bigger slice of the estimated $1.77 trillion global space market. Rasmussen’s confidence is shared by others: Clear Street currently sees fair value at $129, and New Street Research initiated coverage with a buy recommendation, citing the vast addressable market—Rocket Lab today captures less than 1% of total space-economy spending.

Yet the bullish narrative is at odds with what insiders are doing. C-suite executives and directors have been cashing out near the stock’s all-time high of $151. Notably, Chief Financial Officer Adam Spice and a vice president sold their stakes close to that peak. The insider selling has coincided with a broader cooling in space stocks: Rocket Lab closed recently at $108.23, well below its record, after a geopolitical scare—a US military helicopter incident over the Strait of Hormuz—spooked the sector.

Meanwhile, options-market activity is telegraphing rising caution. The put-call ratio has climbed to 0.69 from its normal 0.52, and implied volatility has hit its highest level of the past year. Short interest stood at nearly 32 million shares as of late May, representing about 6% of the free float. These metrics suggest that traders are paying up for downside protection, anticipating further swings.

Should investors sell immediately? Or is it worth buying Rocket Lab USA?

Operationally, Rocket Lab continues to post impressive growth. First-quarter revenue rose 63% year over year to $200.35 million, though the company still reported a net loss of $0.07 per share. Cash burn remains elevated due to the capital-intensive Neutron program, but a recent $90 million contract with the US Space Force provides strategic support. The company’s backlog has swelled to a record $2.2 billion.

Analyst consensus, however, remains divided. The average price target across Wall Street is near $99—meaning the stock would need to pull back from its current level of $108 to meet that mean estimate. That gap between Rasmussen’s ambitious $132 target and the more modest street average underscores the divergence in opinions. Some view Rocket Lab as a high-growth opportunity still early in its expansion; others see a valuation that has run ahead of fundamentals.

On a separate note, CFO Adam Spice recently joined the board of Syntiant, a move that market observers interpret as a vote of confidence in Rocket Lab’s leadership depth. Institutional investors have also been repositioning: Clearbridge Investments boosted its stake by 55%, while Erste Asset Management and J.W. Cole Advisors increased their holdings significantly. Still, with the next quarterly report just days away—either August 5 or August 6—Rocket Lab will need to deliver not just a revenue beat but also a convincing narrative that the company’s trajectory justifies its market value.